LSB (LakeShore Biopharma Co) EBIT : $-22.14 Mil (TTM As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co EBIT?

LakeShore Biopharma Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-13.47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-22.14 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LakeShore Biopharma Co's annualized ROC % for the quarter that ended in Sep. 2023 was -39.50%. LakeShore Biopharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -43.60%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -30.71%.

LakeShore Biopharma Co EBIT Historical Data

The historical data trend for LakeShore Biopharma Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co EBIT Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

EBIT

-22.22

-15.50

-16.47

-57.05

LakeShore Biopharma Co Quarterly Data
	Mar21	Sep21	Mar22	Jun22	Sep22	Mar23	Jun23	Sep23	Mar24
EBIT	Get a 7-Day Free Trial				2.32	-	-8.67	-13.47	-

Competitive Comparison of LakeShore Biopharma Co's EBIT

For the Biotechnology subindustry, LakeShore Biopharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's EV-to-EBIT falls into.

LakeShore Biopharma Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.14 Mil.

LakeShore Biopharma Co (NAS:LSB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LakeShore Biopharma Co's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-54.84 * ( 1 - 0.22% )	/	( (156.719	+	120.353)	/ 2 )
=	-54.719352	/	138.536
=	-39.50 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	235.97	-	66.02	-	( 13.231	-	max(0, 91.007	-	140.5	+	13.231	))
=	156.719

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	220.787	-	64.82	-	( 35.614	-	max(0, 90.864	-	128.065	+	35.614	))
=	120.353

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

LakeShore Biopharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-53.888	/	( ( (80.683 + max(60.928, 0))	+	(78.281 + max(27.316, 0)) )	/	2 )
=	-53.888	/	( ( 141.611	+	105.597 )	/	2 )
=	-53.888	/	123.604
=	-43.60 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(69.247	+	25.466	+	32.556)	-	(66.02	+	0.321	+	1.4210854715202E-14)
=	60.928

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(58.835	+	29.162	+	4.454)	-	(64.82	+	0.315	+	1.4210854715202E-14)
=	27.316

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-22.143	/	72.108
	=	-30.71 %

LakeShore Biopharma Co EBIT Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

H6Z0:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.lakeshorebio.com

LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.